Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -22.06% | -12.06% | 12.39% | 48.10% | 65.99% |
| Total Depreciation and Amortization | -50.00% | -25.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 126.68% | 138.05% | 137.16% | 244.74% | 692.20% |
| Change in Net Operating Assets | 122.89% | 10.64% | 76.24% | -162.38% | -128.25% |
| Cash from Operations | 36.93% | 20.57% | 46.17% | 49.95% | 56.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 6.34% | -19.63% | -28.09% | -1.25% | -0.72% |
| Issuance of Common Stock | -53.29% | -53.29% | -54.26% | -44.76% | 1,257.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 107.98% | 123.94% | 129.05% | -258.62% | -259.14% |
| Cash from Financing | -51.65% | -51.65% | -52.78% | -53.80% | 1,073.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13,752.94% | -321,733.33% | 31.63% | 42.49% | 99.95% |